Centogene N.V. (CNTG)

NASDAQ: CNTG · IEX Real-Time Price · USD
2.43
+0.37 (17.96%)
Jun 24, 2022 4:00 PM EDT - Market closed
17.96%
Market Cap 65.78M
Revenue (ttm) 215.82M
Net Income (ttm) -52.74M
Shares Out 27.07M
EPS (ttm) -2.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 592
Open 2.41
Previous Close 2.06
Day's Range 2.00 - 2.69
52-Week Range 1.83 - 11.95
Beta -1.19
Analysts Buy
Price Target 10.20 (+319.8%)
Earnings Date Jun 29, 2022

About CNTG

Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing. The company develops rare disease platform, a data and biological repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide ... [Read more...]

Industry Biotechnology
IPO Date Nov 7, 2019
Employees 808
Stock Exchange NASDAQ
Ticker Symbol CNTG
Full Company Profile

Financial Performance

In 2021, Centogene's revenue was 189.92 million, an increase of 47.94% compared to the previous year's 128.38 million. Losses were -46.41 million, 116.0% more than in 2020.

Financial numbers in EUR Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for CNTG stock is "Buy." The 12-month stock price forecast is 10.2, which is an increase of 319.75% from the latest price.

Price Target
$10.2
(319.75% upside)
Analyst Consensus: Buy
Stock Forecasts

News

CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND® (mitapivat) to Treat Children With Rare ...

Working together on the world's first treatment that targets the underlying causes of pyruvate kinase (“PK”) deficiency in children under the age of 18 Working together on the world's first treatment th...

CENTOGENE's CentoCloud® Is Now CE-Marked as One of the Only Decentralized SaaS Platforms Compliant With European IVD ...

CE-marked clinical decision support platform enables laboratories to provide best-in-class diagnostics of genetic diseases CE-marked clinical decision support platform enables laboratories to provide be...

CENTOGENE Contributes to Europe-Wide Efforts to Update Guidelines for Whole Genome Sequencing (WGS) in Rare Disease D...

Newly established WGS recommendations published in the European Journal of Human Genetics

CENTOGENE to Present at the H.C. Wainwright Global Investment Conference

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 19, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential biodata life science partner for rare and neurodegenerati...

CENTOGENE and Takeda Extend Market Access and Expansion Partnership to Advance Patient Care Globally

Accelerating the path from diagnosis to available treatments for rare metabolic and rare neurodegenerative diseases

CENTOGENE Reports Fourth Quarter and Full Year 2021 Financial Results

- Full Year 2021 Total Revenue Growth of 48%, and 11% in Core Business Segments, Exceeds Guidance

CENTOGENE CEO Kim Stratton to Speak at BIO-Europe Spring® 2022 Conference

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 24, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, und...

CENTOGENE to Announce Fourth Quarter and Fiscal Year 2021 Financial Results on March 30, 2022

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 23, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, und...

CENTOGENE Announces Expansion of Data Access and Collaboration Agreement With Pfizer

ROSTOCK, Germany and BERLIN, March 17, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat ra...

CENTOGENE Announces Voting Results of Extraordinary General Meeting

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, unde...

CENTOGENE Announces CFO Transition and Appointment of Miguel Coego Rios as EVP Finance & Legal and Interim CFO

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, und...

Centogene Raises $62M Via Debt And Equity Financings To Support Growth Plan

Centogene N.V. (NASDAQ: CNTG) has closed a €15 million (approximately $17 million) private placement financing from investors led by DPE Deutsche Private Equity, TVM Capital Life Science, and Careventures.

CENTOGENE Announces USD 62 Million Aggregate Equity and Debt Financings to Support Growth Plan

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, unde...

CENTOGENE Announces Nomination of Andreas Busch to Supervisory Board

Nomination adds significant expertise to support pharma partnerships and an impressive track record in value creation Nomination adds significant expertise to support pharma partnerships and an impressi...

CENTOGENE Announces Nomination of Kim Stratton as Chief Executive Officer

Dr. Andrin Oswald resigns as CEO due to prolonged medical leave; Kim Stratton elected as successor Dr. Andrin Oswald resigns as CEO due to prolonged medical leave; Kim Stratton elected as successor

CENTOGENE Joins Forces With Insilico Medicine for Niemann-Pick Disease Type C (NPC) Target Discovery, Applying Artifi...

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, und...

CENTOGENE's CentoCloud® Set to Revolutionize Rare Disease Diagnostics With Decentralized SaaS Platform for Laboratori...

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, unde...

CENTOGENE Wins Award in Digital Healthcare Innovation for Artificial Intelligence (AI) Platform Leading Biomarker Dis...

Leveraging AI to Accelerate the Path From Diagnosis to Cure Leveraging AI to Accelerate the Path From Diagnosis to Cure

CENTOGENE Announces CEO to Take Temporary Medical Leave of Absence – Biopharmaceutical Industry Veteran Kim Stratton ...

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, unde...

Why Centogene Shares Are Slumping After Q3 Earnings?

Centogene N.V. (NASDAQ: CNTG) reported Q3 sales of €30.2 million, down 17% Y/Y, driven by decreasing revenues from COVID-19 testing.

Centogene N.V. (CNTG) Reports Q3 Loss, Tops Revenue Estimates

Centogene N.V. (CNTG) delivered earnings and revenue surprises of -83.05% and 11.58%, respectively, for the quarter ended September 2021.

CENTOGENE Reports Third Quarter 2021 Financial Results

Second Consecutive Quarter of Core Business Growth, Phasing Out COVID-19 Testing and Restructuring Organization for Core Rare Disease Business Second Consecutive Quarter of Core Business Growth, Phasing...

Earnings Preview For Centogene

Centogene (NASDAQ:CNTG) is set to give its latest quarterly earnings report on Wednesday, 2021-11-24. Here's what investors need to know before the announcement.

CENTOGENE to Announce Third Quarter 2021 Financial Results on November 24, 2021

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, und...

CENTOGENE Expands Partnership With Agios to Generate Novel Insights Into Rare Blood Diseases

Providing Global Clinical Trial Support for Thalassemia and Sickle Cell Disease Will Deepen Understanding of Disease Characterization in the Search for a Treatment Providing Global Clinical Trial Suppor...